ArticleActa pharmacologica Sinica2025

Glabridin as a selective Kv2.1 inhibitor ameliorates DPN pathology by disrupting the Aβ/Kv2.1/JNK/NF-κB/NLRP3/p-Tau pathway.

Jia-Wen Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.